Anzeige
Mehr »
Sonntag, 29.03.2026 - Börsentäglich über 12.000 News
Das Netz reicht nicht mehr: Dieser Titel setzt auf Energie aus Wasser - bevor der Markt es versteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

S&P 500 

WKN:  ISIN: US78378X1072 
S&P 500
27.03.26 | 21:59
6.354,35
-2,11 % -136,69
1-Jahres-Chart
S&P 500 Chart 1 Jahr
5-Tage-Chart
S&P 500 5-Tage-Chart
Markt oder Branche auswählen:

Aktuelle News zu Aktien im S&P 500

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
00:46Salesforce pushes 'agentic enterprise' shift as Philippine firms face AI transition3
00:46Probe on WB-Paramount deal underway3
00:46Norwegian Cruise Line shakes up board amid pressure from activist Elliott2
SaJim Cramer Provides the "Bear Case" for Paychex, Inc. (PAYX)2
SaJim Cramer Says He Likes Cheniere More Than Expand Energy Corporation (EXE)8
SaJim Cramer Says "It's Also Kind of the Right Environment for Dollar General (DG)"4
SaJim Cramer Says Stocks Like Generac (GNRC) "Make a Ton of Sense to Own Right Here" in Theory3
SaTop Companies Owned by DuPont5
SaMark Zuckerberg texted Elon Musk to offer help with DOGE10
SaAll-new electric Ford Transit City is ready to deliver big savings3
SaYouTube in Android Auto jetzt nutzbar - zunächst nur im Audiomodus7
SaEli Lilly: Kombinationstherapie mit Taltz und Zepbound zeigt Wirksamkeit bei Psoriasis-Arthritis-Studie2
SaLilly's Taltz plus Zepbound shows efficacy in psoriatic arthritis trial2
SaInvestors Are Completely Wrong About Nvidia Stock26
SaBiogen meldet positive Phase-2-Daten für Haut-Lupus-Wirkstoff3
Sa'It's a nightmare': Complaints pile up over Booking.com grievances11
SaBiogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity425In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear...
► Artikel lesen
SaBiogen reports positive Phase 2 results for lupus skin drug4
SaIncyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting410 Phase 3 data from the STOP-HS program demonstrate povorcitinib's substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). ...
► Artikel lesen
SaBofA previews Apple's first foldable iPhone2
Weiter >>